References
- Kułakowski A, Zatoński W. Cancer in Poland in 1990. In: Zatoński W, Tyczyński J, editos. Warsaw: Pracownia Poligraficzna Centrum Onkologii - Instytutu im. Marii Skłodowskiej-Curie; 1990.
- Didkowska J, Wojciechowska U, Czaderny K, Olasek P, Ciuba A. Cancer in Poland in 2017. Warsaw: Pracownia Poligraficzna Centrum Onkologii - Instytutu im. Marii Skłodowskiej-Curie; 2017. [cited 2020 Feb 1]. Available at:
http://onkologia.org.pl/wp-content/uploads/Nowotwory_2017.pdf - Park SW, Hwang DS, Song WH, Nam JK, Lee HJ, Chung MK. Conditional biochemical recurrence-free survival after radical prostatectomy in patients with high-risk prostate cancer. Prostate Int 2020; 8: 173-7. doi: 10.1016/j.prnil.2020.07.004
- Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62. doi: 10.1016/j.juro.2008.11.032
- Bolla M, Van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-27. doi: 10.1016/S0140-6736(12)61253-7
- Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol 2014; 66: 243-50. doi: 10.1016/j.eururo.2014.03.011
- Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol 2016; 34: 3648-54. doi: 10.1200/JCO.2016.67.9647
- Mottet N, Conford P, van den Bergh RCN, Briers E, De Santis M, Fantis S, et al. Prostate Cancer EAU Guidelines. Presented at the EAU Annual Congress Barcelona 2019. Arnhem, the Netherlands: EAU Guidelines Office; 2019. [cited 2020 Feb 1]. Available at:
https://uroweb.org/guideline/prostate-cancer/ - Kneebone A, Fraser-Browne C, Delprado W, Duchesne G, Fisher R, Frydenberg M, et al. A phase III multi-centre randomised trial comparing adjuvant versus early salvage radiotherapy following a radical prostatectomy: results of the TROG 08.03 and ANZUP “RAVES” trial. Int J Radiat Oncol 2019; 105: S37-8. doi: 10.1016/j.ijrobp.2019.06.456
- Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 2020; 396: 1413-21. doi: 10.1016/S0140-6736(20)31553-1
- Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 2020; 21: 1341-52. doi: 10.1016/S1470-2045(20)30454-X
- Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet 2020; 396: 1422-31. doi: 10.1016/S0140-6736(20)31952-8
- RAVES-Contouring Guidelines Revised July 2011. CTV Delineation. [cited 2020 Aug 15]. Available at:
https://www.trog.com.au/SiteFiles/trogcomau/TROG_0803_-_Guidelines_for_Contouring.pdf - Tourinho-Barbosa R, Srougi V, Nunes-Silva I, Baghdadi M, Rembeyo G, Eiffel SS, et al. Biochemical recurrence after radical prostatectomy: what does it mean? Int Braz J Urol 2018; 44: 14-21. doi: 10.1590/S1677-5538.IBJU.2016.0656
- Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol 2019; 75: 967-87. doi: 10.1016/j.eururo.2018.10.011
- Xie W, Regan MM, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Metastasisfree survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol 2017; 35: 3097-104. doi: 10.1200/JCO.2017.73.9987
- Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J Am Med Assoc 1999; 281: 1591-7. doi: 10.1001/jama.281.17.1591
- Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, et al. Comparison between adjuvant and early-salvage postprostatectomy radiotherapy for prostate cancer with adverse pathological features. JAMA Oncol 2018; 4: e175230. doi: 10.1001/jamaoncol.2017.5230
- Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, et al. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model. J Clin Oncol 2017; 35: 1982-90. doi: 10.1200/JCO.2016.69.9918
- Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 2020; 21: 1331-40. doi: 10.1016/S1470-2045(20)30456-3
- Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol 2019; 11: 1758835919876828. doi: 10.1177/1758835919876828
- Napieralska A, Miszczyk L, Tukiendorf A, Stąpór-Fudzińska M. The results of treatment of prostate cancer bone metastases after CyberKnife radiosurgery. Ortop Traumatol Rehabil 2014; 16: 339-49. doi: 10.5604/15093492.1112535
- Napieralska A, Miszczyk L, Stąpór-Fudzińska M. CyberKnife stereotactic ablative radiotherapy as an option of treatment for patients with prostate cancer having oligometastatic lymph nodes: single-center study outcome evaluation. Technol Cancer Res Treat 2016; 15: 661-73. doi: 10.1177/1533034615595945